Chemotherapeutic Toxicity Clinical Trial
Official title:
Electronic Patient Reporting of Side Effects to Chemotherapy Among Breast Cancer Patients Using the Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events (PRO-CTCAE): A Cluster Randomized Controlled Trial
Verified date | October 2017 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to determine whether the use of breast cancer patients' own electronic reporting of side effects to chemotherapy in a treatment setting has an impact on the handling of side effects and on the number of hospitalizations, febrile neutropenia and dose adjustments. We are using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for the patients' reporting of side effects.
Status | Completed |
Enrollment | 700 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Gender •Female: only female participants are being studied Minimum age •18 years Maximum age •N/A Accepts Healthy Volunteers •No Eligibility Criteria Inclusion criteria - Breast cancer patients starting adjuvant chemotherapy in the period November 1, 2015 - September 1, 2016 in Danish oncology clinics Exclusion Criteria: - More than six scheduled cycles of chemotherapy - Not able to read and understand Danish language |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Danish Cancer Society |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose adjustments reported in the medication treatment sheet before each cycle of chemotherapy (5 time points with three weeks interval) | up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017 | ||
Secondary | Number of hospitalizations reported in the medical record after each of the six cycles of chemotherapy | up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017 | ||
Secondary | Febrile neutropenia reported in the medical record after each of the six cycles of chemotherapy | up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017 | ||
Secondary | Detailed description of side effects in the medical record before start of chemotherapy and after each six cycles of chemotherapy | up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017 | ||
Secondary | Handling of side effects documented in the medical record | up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017 | ||
Secondary | Patients' experience of communication and handling of side effects measured in questionnaire survey and qualitative interviews | up to18 weeks of chemotherapy in the period November 1, 2015 - January 31, 2017 | ||
Secondary | Patient and staff compliance as registerede by the software used | up to 18 weeks (November 1, 2015 - January 31, 2017) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04277650 -
System for High-Intensity Evaluation During Radiotherapy
|
N/A | |
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
Recruiting |
NCT06012253 -
The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life
|
N/A | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Not yet recruiting |
NCT04965532 -
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
|
N/A | |
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Terminated |
NCT04607668 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
|
Phase 3 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
Recruiting |
NCT06357871 -
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
|
||
Completed |
NCT00292526 -
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
|
Phase 4 | |
Completed |
NCT04663178 -
Foot Bath and Chemotherapy Induced Fatigue
|
N/A | |
Recruiting |
NCT03191461 -
Myocardial Perfusion and Fibrosis in Cancer Survivors
|
||
Recruiting |
NCT05251922 -
Tolerance of Anti-Cancer Therapy in the Elderly
|
||
Not yet recruiting |
NCT06387901 -
Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
|
||
Recruiting |
NCT05892146 -
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
|
N/A | |
Not yet recruiting |
NCT05921149 -
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT05302336 -
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
|
Phase 4 |